Business

Analyst Target Update & Review on Rhythm Pharmaceuticals, Inc. (:RYTM) as ABR Touches 13

Rhythm Pharmaceuticals, Inc. (:RYTM) currently has an Average Broker Rating of 1.63. The ABR rank within the industry stands at 13. This number is based on the 4 sell-side firms polled by Zacks.  

Each brokerage research report carries with it some form of recommendation. The brokerage firms may use different lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to help compute the ABR. 

As the name implies the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of research reports.

Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the broker thinks the company will perform relative to its sector. Their recommendations are issued over a particular period of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.

For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of different other names: “accumulate”, “outperform”, “moderate buy” or “overweight”.

Analysts on a consensus basis are expecting that the stock will reach $38.5 within the year.

Active investors are constantly faced with tough decisions when managing their own stock portfolios. Deciding when to sell a certain stock may be just as vital as choosing which stocks to buy in the first place. There are bound to be extremes on both sides when analyzing buy and sell decisions. Maybe a well researched stock hasn’t seen the gains that were expected at the outset. When emotions take over, the investor may not be able to part with the stock. They may hold on to the equity with the hopes that someday it will bounce back. Of course this may happen eventually, but the situation could also worsen and the stock may keep losing. The same decisions sometimes have to be made when dealing with a winning stock. After a big run, the investor may have to decide whether to take the profits or hold off to see if the stock will continue to push upwards. These are no easy decisions for the individual investor. Being able to make the proper portfolio moves may take some time to master, but it may end up being highly important for continued, long-term success.  

Most recently Rhythm Pharmaceuticals, Inc. (:RYTM) posted quarterly earnings of $-0.74 which compared to the sell-side estimates of -0.56. The stock’s 12-month trailing earnings per share stands at $-2.38. Shares have moved $1.04 over the past month and more recently, $8.93 over the past week heading into the earnings announcement. There are 1 analyst projections that were taken into consideration from respected brokerage firms.

When examining current stock market levels, investors who have been staying on the sidelines may be wondering if now is a good time to get back into the ring. Nobody can say for sure if momentum will continue to push to the upside, and investors may be overly cautious at this stage. Studying company financials and paying attention to pertinent economic data can help the investor make more educated decisions when it comes to the stock market. It is obviously very hard for a new investor to become highly successful in the stock market right out of the gate. Doing all the homework and dedicating the proper amount of time can help the investor get on the right track to accumulating profits down the road.

Buy Ratings
3 analysts rate Rhythm Pharmaceuticals, Inc. a Buy or Strong Buy, which is 75% of all the analyst ratings.

Earnings
Research analysts are predicting that Rhythm Pharmaceuticals, Inc. (:RYTM) will report earnings of $-0.83 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Rhythm Pharmaceuticals, Inc. (:RYTM) closed the last session at $30.02 and sees an average of 66840.9 shares trade hands in each session. The 52-week low of the stock stands at $17.02 while the current level stands at 69.04% of the 52-week High-Low range. Looking further out we can see that the stock has moved 19.6% over the past 12 weeks and 11.68% year to date.

It is no secret that most investors have the best of intentions when diving into the equity markets. Making sound, informed decisions can help the investor make the most progress when dealing with the markets. Often times, investors may think they have everything in order, but they still come out on the losing end. Investors may need to figure out ways to keep emotion out of stock picking. Sometimes trading on emotions can lead to poor results. Making hasty decisions and not paying attention to the correct data can lead to poor performing portfolios in the long-term.

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *

*